Час введення антибіотикопрофілактики перед хірургічним розрізом — коли почати інфузію, коли ре-дозувати та коли зупинити профілактику
Surgical antibiotic prophylaxis (SAP) works only if adequate drug concentration is present in the surgical-site tissues at the exact moment the skin is incised — the point at which bacteria are first introduced into the wound. For standard beta-lactam agents such as cefazolin and cefuroxime, national guidelines (ASHP/IDSA/SIS/SHEA) converge on a single practical rule: begin infusion within 60 minutes before incision, ideally 15–60 minutes prior, so serum and tissue levels peak right as the surgeon makes the first cut.
It might seem intuitive that giving antibiotics earlier is always safer, but pharmacokinetics argue otherwise. Antibiotic tissue concentration follows an absorption-distribution-elimination curve: concentration rises after infusion, peaks in tissue within roughly 15–30 minutes for cefazolin, and then declines as the drug is cleared.
If the antibiotic is infused too early (e.g., 3 hours before incision), serum and tissue levels may have already fallen below the minimum inhibitory concentration (MIC) for likely pathogens by the time the incision is made — leaving the wound unprotected during the critical exposure window.
If the antibiotic is infused too late (started after incision, or not completed until after the cut), the wound is exposed to skin and environmental flora before therapeutic tissue levels are achieved, defeating the purpose of prophylaxis entirely.
The evidence base for the 60-minute rule comes largely from Classen et al. (NEJM, 1992), a landmark study of >2,800 surgical patients showing the lowest SSI rate (0.6%) occurred when prophylaxis was administered in the 2 hours before incision, with the tightest and most protective window concentrated in the final 60 minutes preoperatively.
Cefazolin, the most commonly used surgical prophylactic agent worldwide, is typically infused over 3–5 minutes (or up to 30 min for higher weight-based doses) and reaches peak tissue concentration roughly 15–30 minutes after infusion — which is why "within 60 minutes before incision" reliably captures the therapeutic peak at the time of the first cut.
Because the anesthesiology team, not the surgeon, typically administers preoperative antibiotics, timing compliance is fundamentally a team-based, protocolized process:
• Standardized order sets: preoperative antibiotic orders are timed to the anesthesia induction sequence, not to an arbitrary clock time, since surgical start time can shift • "Time-out" checklists: many institutions include antibiotic administration time as a mandatory checklist item during the surgical time-out immediately before incision • Electronic health record (EHR) alerts: automated prompts fire if incision is documented without a preceding antibiotic administration timestamp within the compliant window • Redundant verification: circulating nurse, anesthesiologist, and surgeon all cross-check that prophylaxis was given and timed correctly before allowing the incision to proceed
This simulator's "minutes before incision" slider represents exactly this real-world variable: the interval between antibiotic infusion start and the surgical time-out / incision moment, which quality-improvement programs audit as a core performance metric.
Not every prophylactic antibiotic follows the standard 60-minute rule. Vancomycin and fluoroquinolones (e.g., ciprofloxacin, levofloxacin) — reserved for beta-lactam-allergic patients or MRSA-colonized patients — require deliberately slow intravenous infusion to avoid dangerous infusion-related reactions. Guidelines therefore extend their allowable pre-incision window to up to 120 minutes, giving the infusion pump time to finish safely before the surgeon begins.
Vancomycin triggers direct, non-IgE-mediated mast cell and basophil degranulation when infused too rapidly, producing "vancomycin infusion reaction" (historically called red man syndrome): flushing, pruritus, and erythema of the face, neck, and upper torso, occasionally accompanied by hypotension and, rarely, cardiac arrest in severe cases.
The reaction is rate-dependent, not dose-dependent — it is driven by the peak plasma concentration achieved during infusion, not the total dose delivered. Slowing the infusion rate (typically to no faster than 10 mg/min, or over at least 60 minutes for standard weight-based doses, longer for larger doses) reliably prevents the reaction in the vast majority of patients.
Because a full, unhurried infusion for a typical surgical dose (15–20 mg/kg) can take 60–120 minutes, starting the infusion at the standard "60 minutes before incision" mark would force clinicians to either rush the infusion (risking a reaction) or delay the incision. Extending the allowable start window to up to 120 minutes before incision resolves this conflict while still keeping tissue concentrations therapeutic at the time of the cut.
Fluoroquinolones (ciprofloxacin, levofloxacin) are typically reserved for patients with severe beta-lactam allergy undergoing procedures where gram-negative coverage is essential (e.g., some genitourinary or GI procedures). Like vancomycin, they require infusion over 60 minutes or longer to minimize infusion-site phlebitis and reduce the risk of QT-interval prolongation associated with rapid administration.
Because both drug classes are used more selectively than cefazolin — chosen specifically for penicillin/cephalosporin-allergic patients or documented MRSA colonization — correctly identifying which patients fall into this "extended-infusion" category is itself a timing-critical decision point, ideally flagged well before the patient reaches the operating room so the longer infusion can be scheduled without delaying surgery.
The clinical logic is symmetric to Stage 1: the goal is always the same therapeutic target — adequate tissue drug concentration at the moment of incision. The extended 120-minute window for vancomycin and fluoroquinolones is not a looser standard; it is the same physiological target reached via a slower, safer infusion rate.
A single preoperative dose is not always sufficient. Once a procedure extends well beyond the antibiotic's half-life, serum and tissue concentrations decay below protective thresholds — leaving later portions of a long operation exposed. Guidelines therefore recommend an intraoperative redose once elapsed time exceeds roughly two half-lives of the chosen agent, or after substantial intraoperative blood loss dilutes and clears the drug.
Antibiotic elimination follows first-order kinetics: concentration falls by half every one half-life. After two half-lives, only 25% of the peak concentration remains; after three, just 12.5% — likely below the MIC needed to inhibit surgical-site pathogens.
For cefazolin (half-life ~1.2–2.2 hours in patients with normal renal function), this means a redose is generally recommended at approximately the 4-hour mark if the procedure is still ongoing, to re-establish protective tissue concentrations for the remainder of the case. Agents with longer half-lives — including vancomycin and fluoroquinolones (roughly 4–8 hours) — rarely require intraoperative redosing even in long procedures, which is one more reason those agents are sometimes preferred for anticipated lengthy surgeries.
Major intraoperative blood loss compounds the problem by physically removing circulating drug and diluting remaining concentration with resuscitation fluids and transfused blood products. Many institutional protocols therefore trigger a redose after blood loss exceeding roughly 1,500 mL, independent of elapsed time, since a fast-progressing hemorrhage can outpace the clock-based redosing schedule.
Redosing thresholds are typically set at two half-lives rather than one, because tissue concentrations after a single dose are usually still adequate through the first half-life and start to become marginal only as the second half-life elapses — the "2× half-life" rule balances protection against unnecessary drug exposure.
Because circulating and scrub nursing staff — not the anesthesiologist alone — often track elapsed surgical time, redosing reminders are commonly built into OR workflow tools:
• Whiteboard or EHR timers: display elapsed time since the initial prophylactic dose, with a visual/audible alert at the redose threshold • Case-length anticipation: for procedures expected to exceed the redose interval from the outset (e.g., complex cardiac or transplant surgery), redose timing is pre-planned rather than reactively triggered • Blood-loss tracking: anesthesia records cumulative estimated blood loss; crossing the institutional threshold (often 1,500 mL) prompts a redose regardless of elapsed time • Renal function adjustment: in patients with renal impairment, drug half-life is prolonged, and standard redosing intervals may need to be extended accordingly
This simulator surfaces redosing as an informational reminder tied to the selected agent type, since the actual redosing decision depends on real-time procedure duration and blood loss — variables that unfold only once surgery is underway.
A persistent and costly misconception in surgical practice is that continuing antibiotics for days after an operation offers extra protection against infection. Multiple randomized trials and meta-analyses have repeatedly shown the opposite: prophylactic antibiotics should be discontinued within 24 hours after surgery in the overwhelming majority of cases, because prolonging administration beyond that point does not further reduce surgical site infection rates while measurably increasing harm.
Historically, some surgeons continued prophylactic antibiotics for 48–72 hours or until surgical drains were removed, believing this reduced infection risk further. Contemporary evidence — synthesized in the 2013 ASHP/IDSA/SIS/SHEA Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery and reaffirmed in subsequent updates — shows no additional reduction in SSI rates from continuing prophylaxis beyond 24 hours (24–48 hours for cardiothoracic procedures in some earlier guidance, though most current recommendations converge on 24 hours even for cardiac surgery).
What prolonged dosing does reliably increase is harm: greater risk of Clostridioides difficile infection, selection pressure favoring antibiotic-resistant organisms, higher rates of drug-related adverse events (renal injury, allergic reactions), and unnecessary cost and nursing burden.
The protective mechanism of prophylaxis is established at the time of incision and during the period the wound remains open and freshly closed — not by ongoing systemic antibiotic exposure once the wound is closed and the sterile field is no longer active.
A widely cited principle in antimicrobial stewardship: "the wound is protected by the antibiotic present when bacteria are introduced (at incision), not by antibiotics given after the wound is closed." Stopping prophylaxis within 24 hours reflects this mechanism directly.
Discontinuation timing is now a formally tracked quality and antimicrobial-stewardship metric in many health systems, similar to preoperative timing compliance:
• Automatic stop orders: many EHR order sets auto-discontinue prophylactic antibiotic orders at the 24-hour mark unless a clinician actively documents a therapeutic (not prophylactic) indication to continue • Stewardship audits: pharmacy and infection-control teams periodically audit postoperative antibiotic duration against guideline benchmarks • Legitimate exceptions: prophylaxis is intentionally extended only when a documented active infection is identified intraoperatively or postoperatively — at which point the antibiotic course is reclassified as treatment, with its own duration and indication, not prophylaxis • Clean vs. contaminated cases: even in more complex or contaminated procedures, current evidence still generally does not support extending pure prophylaxis beyond 24 hours; ongoing signs of infection warrant a treatment course rather than prolonged "just in case" prophylaxis
The discontinuation decision is therefore best understood as a default stop rule that requires active clinical justification to override, rather than a default continuation that requires justification to stop.
Antibiotic timing is not merely a procedural formality — it is one of the most consistently evidence-backed, modifiable predictors of surgical site infection risk. Surgical quality-improvement programs worldwide, from the US Surgical Care Improvement Project (SCIP) to WHO Safe Surgery initiatives, track timing compliance as a core performance indicator precisely because the link between correct timing and reduced SSI has been demonstrated across decades of data.
The Classen et al. (New England Journal of Medicine, 1992) study remains the foundational reference: among more than 2,800 patients undergoing clean or clean-contaminated surgery, those who received prophylaxis in the 2 hours preceding incision had the lowest SSI rate (0.6%). Patients who received antibiotics too early (2–24 hours before incision) had an SSI rate of 3.8%, and those who received antibiotics after incision had a rate of 1.4% — both substantially higher than the optimally timed group.
Subsequent large observational studies and quality-improvement program data (including SCIP and its successors) have consistently reproduced this pattern: timing compliance correlates with lower SSI incidence across procedure types, even after adjusting for other risk factors such as procedure duration, wound classification, and patient comorbidities.
Because SSI is associated with substantially increased length of stay, readmission risk, cost, and — in a meaningful subset of cases — mortality, even a modest percentage-point improvement in timing compliance translates into a measurable population-level reduction in surgical morbidity.
The shift from "antibiotic timing as clinician judgment" to "antibiotic timing as a tracked, auditable metric" reflects a broader pattern in modern healthcare quality improvement: outcomes that depend on many hand-offs (surgeon, anesthesiologist, nursing, pharmacy) benefit disproportionately from standardized, checklist-driven processes rather than individual vigilance alone.
Key elements of successful timing-compliance programs:
• Real-time EHR timestamp capture: antibiotic administration time and incision time are both electronically logged, enabling automatic compliance calculation rather than retrospective chart review • Public/team-level feedback: many institutions display aggregate timing-compliance rates to surgical teams, leveraging feedback loops to sustain high performance • Bundled with other SSI-reduction measures: correct antibiotic selection, appropriate redosing, normothermia maintenance, and glycemic control are often tracked together as a "surgical care bundle," since timing compliance alone — while important — is one of several modifiable levers • Global adoption: WHO Guidelines for Safe Surgery and national surgical societies across many countries, including Ukraine, have incorporated antibiotic-timing checklists into standard perioperative protocols
The throughline across all five stages of this simulator is a single unifying principle: adequate antibiotic tissue concentration must be present at incision, sustained through the procedure via appropriate redosing, and then deliberately withdrawn once its protective window has closed — with each transition point representing a specific, evidence-based timing decision.
Surgical antibiotic prophylaxis timing is frequently cited as one of the highest-yield, lowest-cost interventions in all of surgical quality improvement: it requires no new technology or drug — only disciplined coordination of an intervention that is already standard of care.